Drug Details
| General Information of the Drug (ID: DR1784) | ||||
|---|---|---|---|---|
| Name |
Anti-CD8 (53.6.72) antibody
|
|||
| Molecular Type |
Antibody
|
|||
| Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 2 | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Alpha-1 antitrypsin | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Islet Xenotransplantation: Rat islets (400/transplant) were implanted under the renal capsule of recipient mice that were rendered hyperglycemic by single-dose streptozotocin. | |||||
| Experimental
Result(s) |
Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | T-cell surface glycoprotein CD8 alpha (CD8A) | Molecule Info | [2] | |
| T-cell surface glycoprotein CD8 beta (CD8B) | Molecule Info | [2] | ||
